{
  "date": "2026-02-13",
  "items": [
    {
      "id": "1",
      "headline": "Seven influential women in biotech in 2026",
      "preview": "Highlighting the impact of women in biotech leadership roles.",
      "article": "Women constitute 56% of the life sciences workforce, yet they remain underrepresented in leadership roles. As we celebrate International Day of Women and Girls in Science, we recognize influential women in biotech and healthcare in 2026.\nShehnaaz Suliman, CEO of ReCode Therapeutics, has led the company in advancing genetic medicines and securing significant funding. Julie Kim is set to become the first female CEO of Takeda, bringing extensive experience in healthcare. Reshma Kewalramani has transformed Vertex Pharmaceuticals into a leader in cystic fibrosis therapies and is expanding its focus on genetic diseases.\nWhy this matters: These women exemplify the transformative impact of female leadership in biotech, paving the way for future generations and addressing critical health challenges.",
      "sources": [
        {
          "name": "Labiotech.eu",
          "url": "https://www.labiotech.eu/best-biotech/women-in-biotech-2026/",
          "type": "news",
          "verified_date": "2026-02-11"
        }
      ]
    },
    {
      "id": "2",
      "headline": "35 Years of Progress in Cell and Gene Therapy",
      "preview": "A bibliometric analysis reveals trends in cell and gene therapy research.",
      "article": "Cell and gene therapy (CGT) has transformed medical science, offering hope for previously untreatable diseases. A recent study by Kyoto University analyzed over 160,000 articles from 1989 to 2023, highlighting both progress and stagnation in CGT.\nThe research showed robust growth in hematopoietic stem cell transplantation and ex vivo gene therapies, while in vivo gene therapies have struggled. The U.S. and China lead in impactful studies, emphasizing the importance of international collaboration in advancing CGT.\nWhy this matters: Understanding the dynamics of CGT research can guide future investments and collaborations, ensuring that innovations reach patients effectively.",
      "sources": [
        {
          "name": "BIOENGINEER.ORG",
          "url": "https://bioengineer.org/35-years-of-progress-in-cell-and-gene-therapy/",
          "type": "news",
          "verified_date": "2026-02-13"
        }
      ]
    },
    {
      "id": "3",
      "headline": "Eight biotech companies spearheading the antibody drug conjugate new wave",
      "preview": "Exploring innovative companies advancing antibody-drug conjugates.",
      "article": "Antibody-drug conjugates (ADCs) are revolutionizing cancer treatment by combining targeted antibodies with cytotoxic drugs. Eight biotech companies are leading the charge in refining ADC technology, focusing on improving linker chemistry and expanding target types.\nCompanies like Adcendo and Adcentrx Therapeutics are developing next-generation ADCs with unique targets and innovative payloads. Their advancements aim to enhance efficacy and reduce toxicity, addressing limitations seen in earlier ADCs.\nWhy this matters: These innovations in ADC technology could significantly improve cancer treatment outcomes, making therapies more effective and accessible for patients.",
      "sources": [
        {
          "name": "Labiotech.eu",
          "url": "https://www.labiotech.eu/best-biotech/adc-companies/",
          "type": "news",
          "verified_date": "2026-02-11"
        }
      ]
    },
    {
      "id": "4",
      "headline": "Piriform seizures mediated by the piriform-entorhino-dentate circuit induce brain-wide functional reorganization in mice",
      "preview": "New insights into the circuitry of epilepsy and potential treatments.",
      "article": "A study has identified the piriform-entorhino-dentate circuit as a key player in mediating piriform seizures in mice. Using a multimodal approach, researchers mapped how seizures affect brain dynamics and identified critical circuits involved.\nThe findings reveal that disrupting this circuit can suppress seizures, offering potential new avenues for targeted epilepsy treatments. This research underscores the importance of understanding network dynamics in epilepsy.\nWhy this matters: Insights into seizure circuitry can lead to innovative therapies for epilepsy, addressing a significant health challenge for many patients.",
      "sources": [
        {
          "name": "PLOS Biology",
          "url": "https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003577",
          "type": "paper",
          "verified_date": "2026-02-12"
        }
      ]
    },
    {
      "id": "5",
      "headline": "From Darmstadt to Paris: Bel\u00e9n Garijo leaves Merck to lead Sanofi after CEO exit",
      "preview": "Bel\u00e9n Garijo transitions from Merck to Sanofi amid leadership changes.",
      "article": "Bel\u00e9n Garijo, the outgoing CEO of Merck, will take over as CEO of Sanofi following the unexpected departure of Paul Hudson. This leadership change comes as Sanofi seeks to revitalize its pipeline and focus on innovative medicines.\nGarijo's experience at Merck positions her to lead Sanofi through its next phase, which includes advancing immunology assets and expanding mRNA capabilities. The transition reflects a strategic shift aimed at finding new growth engines beyond existing products.\nWhy this matters: Leadership changes in major pharmaceutical companies can significantly impact strategic direction and innovation, influencing the future of drug development.",
      "sources": [
        {
          "name": "European Biotechnology Magazine",
          "url": "https://european-biotechnology.com/latest-news/move-to-sanofi-belen-garijo-not-ready-to-slow-down-but-taking-the-helm-in-paris/",
          "type": "news",
          "verified_date": "2026-02-12"
        }
      ]
    }
  ]
}